Pharmaceuticals Global On demand · 24-48h

Global Pressure Sore Ointment Market Strategic Research Report

Global Pressure Sore Ointment Market Strategic Research Repo…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Pressure Sore Ointment Market
$3182025
3.9%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Silver Sulfadiazine Cream, Povidone-Iodine Ointment, Chlorhexidine Ointment, Mupirocin Ointment, Fusidic Acid Cream

By Application: Hospital, Clinic, Pharmacy, Online Sales

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Glenmark Pharms, Glaxosmithkline, Sino-American Tianjin SmithKline, Hubei Renfu Chengtian Pharmaceutical, Hangzhou Zhuyangxin Pharmaceutical, Nipro, Sun Pharma, Padagis, Front Pharmaceutical, NIPRO JMI Pharma, Bausch Health, Taro Pharmaceutical, Teva Pharmaceuticals, Prati-Donaduzzi, Unilab, Encube Ethicals, Jiangxi Decheng Pharmaceutical, Hengjian Pharmaceutical, Square Pharmaceuticals

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 131 pages
Market size 2025
$318
Million USD
Forecast CAGR
3.9%
2025-2032
Forecast 2032
$415.7
Projected
Regionen
5
Asia Pacific · Latin America · MEA · Europe · North America

Übersicht

Scope of the Report

The global Pressure Sore Ointment market size is predicted to grow from US$ 318 million in 2025 to US$ 416 million in 2032; it is expected to grow at a CAGR of 3.9% from 2026 to 2032.

Pressure sore ointment refers to a category of topical semi-solid products—typically ointments, creams, or gels—designed to help prevent and support the management of pressure sores (also called pressure injuries or bedsores). The primary clinical purpose is to protect vulnerable skin exposed to prolonged pressure, friction, and shear, reinforce the skin barrier, reduce the likelihood of breakdown, and provide a protective, moisture-balanced interface for early-stage erythema or superficial skin disruption. Most formulations are built around “barrier protection + moisturization/repair + optional mild antimicrobial or anti-inflammatory support (depending on the formula) + exudate control,” with common ingredient systems including occlusives and emollient bases (e.g., petrolatum/mineral oil, silicones), skin protectants and absorbent powders (e.g., zinc oxide, starch/mineral particulates), humectants and barrier-repair actives (e.g., glycerin, panthenol, ceramides/lipids), and functional excipients such as emulsifiers, thickeners, chelators, preservatives, antioxidants, and pH buffers to ensure stability and tolerability. Historically, these products evolved from earlier “protective pastes” centered on occlusion and zinc-oxide-based shielding used in incontinence-associated dermatitis and high-risk pressure areas; as modern wound-care concepts (moisture balance, microclimate management, and gentle skin care) advanced, pressure sore ointments diversified toward low-irritancy, breathable, easier-to-clean, longer-lasting barrier technologies and are now often used alongside dressings (films, foams, hydrocolloids, antimicrobial dressings) within structured prevention and care protocols. Upstream supply typically includes base oils/waxes, functional inorganic powders (such as zinc oxide), polymers and rheology modifiers (carbomers, cellulose derivatives, silicone elastomers), surfactant/emulsification systems, skin-benefit actives, preservative/antioxidant systems, and packaging materials/components (laminated or aluminum tubes, pumps/caps, liners, labels, cartons), plus manufacturing services such as hygienic filling, packaging compatibility verification, and stability testing.In 2025, the global production capacity of pressure sore ointments reached 45 million units, with total sales volume amounting to 39.63 million units. The average selling price was approximately USD 8.2 per unit, and gross margins for manufacturers generally ranged between 20% and 30%.

Global key Pressure Sore Ointment players cover Glenmark Pharms, Glaxosmithkline, Sino-American Tianjin SmithKline, Hubei Renfu Chengtian Pharmaceutical, Hangzhou Zhuyangxin Pharmaceutical, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Pressure Sore Ointment market?

What factors are driving Pressure Sore Ointment market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Pressure Sore Ointment market opportunities vary by end market size?

How does Pressure Sore Ointment break out by Type, by Application?

This report presents a comprehensive overview of the global Pressure Sore Ointment market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Silver Sulfadiazine Cream
  • Povidone-Iodine Ointment
  • Chlorhexidine Ointment
  • Mupirocin Ointment
  • Fusidic Acid Cream

Segment by Formulation Base

  • Petrolatum-Based Ointment
  • Silicone-Based Ointment
  • Zinc Oxide Paste
  • Water-Based Gel

Segment by Use Stage

  • Prevention Ointment
  • Early-Stage Pressure Injury Ointment
  • Exudate-Management Ointment

Segment by Application

  • Hospital
  • Clinic
  • Pharmacy
  • Online Sales

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Pressure Sore Ointment market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Hospital, Clinic, Pharmacy evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Pressure Sore Ointment Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 3.9%
Regional growth momentum
Market share by segment
Key metrics
Base value
$318
2025
Forecast
$415.7
2032
CAGR
3.9%
2025–2032
Regionen
5
global
Key companies
Glenmark PharmsGlaxosmithklineSino-American Tianjin SmithKlineHubei Renfu Chengtian PharmaceuticalHangzhou Zhuyangxin PharmaceuticalNiproSun PharmaPadagis
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Silver Sulfadiazine CreamPovidone-Iodine OintmentChlorhexidine OintmentMupirocin OintmentFusidic Acid Cream
By Application
HospitalClinicPharmacyOnline Sales

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Silver Sulfadiazine Cream
  • 3.1.3 Povidone-Iodine Ointment
  • 3.1.4 Chlorhexidine Ointment
  • 3.1.5 Mupirocin Ointment
  • 3.1.6 Fusidic Acid Cream
  • 3.1.7 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Hospital
  • 4.1.3 Clinic
  • 4.1.4 Pharmacy
  • 4.1.5 Online Sales
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Glenmark Pharms
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Glaxosmithkline
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Sino-American Tianjin SmithKline
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Hubei Renfu Chengtian Pharmaceutical
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Hangzhou Zhuyangxin Pharmaceutical
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Nipro
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Sun Pharma
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Padagis
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Front Pharmaceutical
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 NIPRO JMI Pharma
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Bausch Health
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Taro Pharmaceutical
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Teva Pharmaceuticals
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Prati-Donaduzzi
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Unilab
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Encube Ethicals
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Jiangxi Decheng Pharmaceutical
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Hengjian Pharmaceutical
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Square Pharmaceuticals
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Pressure Sore Ointment market?
The global Pressure Sore Ointment market is estimated at US$ 318 million in 2025 (base year) and is projected to reach US$ 416 million by 2032.
What is the forecast CAGR for the Pressure Sore Ointment market?
The market is expected to grow at a CAGR of 3.9% from 2026 to 2032, expanding from US$ 318 million in 2025 to US$ 416 million in 2032, roughly 1.3 times its base-year value.
What is Pressure Sore Ointment?
Pressure sore ointment refers to a category of topical semi-solid products—typically ointments, creams, or gels—designed to help prevent and support the management of pressure sores (also called pressure injuries or bedsores). The primary clinical purpose is to protect vulnerable skin exposed to prolonged pressure, friction, and shear, reinforce the skin barrier, reduce the likelihood of breakdown, and provide a protective, moisture-balanced interface for early-stage erythema or superficial skin disruption.
What are the main segments of the Pressure Sore Ointment market by type?
By type, the market is segmented into Silver Sulfadiazine Cream, Povidone-Iodine Ointment, Chlorhexidine Ointment, Mupirocin Ointment and Fusidic Acid Cream.
Which applications drive demand in the Pressure Sore Ointment market?
Key applications covered include Hospital, Clinic, Pharmacy and Online Sales.
Who are the key players in the Pressure Sore Ointment market?
Key players profiled include Glenmark Pharms, Glaxosmithkline, Sino-American Tianjin SmithKline, Hubei Renfu Chengtian Pharmaceutical, Hangzhou Zhuyangxin Pharmaceutical, Nipro, Sun Pharma and Padagis, among 19 companies covered in total.
Which regions and countries are covered for Pressure Sore Ointment?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Pressure Sore Ointment market?
What factors are driving Pressure Sore Ointment market growth, globally and by region?
What challenges does the Pressure Sore Ointment market face?
The primary clinical purpose is to protect vulnerable skin exposed to prolonged pressure, friction, and shear, reinforce the skin barrier, reduce the likelihood of breakdown, and provide a protective, moisture-balanced interface for early-stage erythema or superficial skin disruption.
Who should buy the Pressure Sore Ointment market report?
The report is intended for manufacturers and solution providers, distributors and end users in Hospital, Clinic and Pharmacy, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Pressure Sore Ointment market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3.500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.